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Abstract 
Background: The incidence and mortality estimates of ovarian cancer based on human development are essential for planning by policy 
makers. This study is aimed at investigating the standardised incidence rates (SIR) and standardised mortality rates (SMR) of ovarian 
cancer and their relationship with the Human Development Index (HDI) in Asian countries.
Methods: This study was an ecologic study in Asia for assessment of the correlation between SIR, age standardised rates (ASR), and 
HDI and their details, including life expectancy at birth, mean years of schooling, and gross national income (GNI) per capita. We used the 
correlation bivariate method for assessment of the correlation between ASR and HDI, and its details. Statistical significance was assumed 
if P < 0.05. All reported P-values were two-sided. Statistical analyses were performed using SPSS (Version 15.0, SPSS Inc.).
Results: The highest SIR of ovarian cancer was observed in Singapore, Kazakhstan, and Brunei respectively. Indonesia, Brunei, and 
Afghanistan had the highest SMR. There was a positive correlation between the HDI and SIR (r = 0.143, p = 0.006). Correlation between 
SMR of ovarian cancer and HDI was not significant (r = 0.005, p = 052.0).
 2 www.ecancer.org
ecancer 2016, 10:628
Re
se
ar
ch
Conclusion: According to the findings of this study, between the HDI and SIR, there was a positive correlation, but there was no correlation 
between the SMR and HDI.
Keywords: ovarian cancer, Human Development Index, epidemiology, incidence, Asia
Introduction
Ovarian cancer is the eighth most common cancer among women, and it includes about 4% of all women’s cancers [1]. This disease has 
high morbidity and mortality rates among cancers of the reproductive system [1, 2]. According to global estimates 225,000 new cases were 
detected each year, and 140,000 people annually die from the disease [1]. Lifetime risk of ovarian cancer in women is one in 71, and the 
chance of dying from the disease is 1 in 95 [3].
Although the incidence and mortality of this disease is high, its aetiology is not fully understood [4]. Nowadays, a few factors associated 
with this cancer have been identified [5]. These are classified into three categories: protective factors (parity and use of contraceptive), risk 
factors (lack of birth, a history of family, and age), and factors such as lactation, age at menarche, and age at menopause, while causality 
between them and the ovarian cancer is still not proven [5–8].
The incidence and mortality of this disease varies in different regions of the world. This may be because of a difference in genetic and 
environmental factors. In recent years, cancer as the cause of death was well-known in high-income countries, but in the coming years, 
regardless of socioeconomic status, it will be a major cause of disease and death. One of the important factors is the Human Development 
Index (HDI) [9–11], which shows the socioeconomic status of people living in different countries [12].
Since the HDI shows the status of the various countries in terms of progress and development, and because of the increasing burden 
of non-communicable diseases, especially in low-income countries [1, 13–15], the aim of this study was to investigate the relationship 
between HDI and incidence of and mortality from ovarian cancer in Asian countries.
Methods
This study was an ecologic study in Asia for assessment of the correlation between the age-specific incidence and mortality rate (ASR), 
and the HDI and its details, including life expectancy at birth, mean years of schooling, and gross national income (GNI) per capita. Data 
on the ASR for every Asian country for 2012 were obtained from the Global Cancer Project, which is available from (http://globocan.iarc.fr/
Default.aspx), and data on the HDI was obtained from the Human Development Report 2013 [16], including specific information about the 
HDI and its details for every country in the word for 2012.
The method of estimation of the age-specific incidence and mortality rates in the Global Cancer Project 
by the International Agency for Research on Cancer (IARC)
Age-specific incidence rate estimate 
The methods of estimation are specific for each country, and the quality of the estimation depends upon the quality and the amount of 
information available for each country. In theory, there are as many methods as there are countries, and because of the variety and the 
complexity of these methods, an overall quality score for the incidence and mortality estimates combined is almost impossible to establish. 
However, an alphanumeric scoring system that independently describes the availability of incidence and mortality data has been estab-
lished at the country level. The combined score is presented together with the estimates for each country with the aim of providing a wide 
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indication of the robustness of the estimation. The methods to estimate the sex- and age-specific incidence rates of cancer for a specific 
country fall into one of the following extensive categories, in priority order:
1. Rates projected to 2012 (38 countries); 2. Most recent rates applied to 2012 population (20 countries); 3. Estimated from national mor-
tality by modeling, using incidence and mortality ratios derived from recorded data in country-specific cancer registries (13 countries); 
4. Estimated from national mortality by modeling using incidence mortality ratios derived from recorded data in local cancer registries in 
neighbouring countries (nine European countries); 5. Estimated from national mortality estimates using modeled survival (32 countries); 
6. Estimated as the weighted average of the local rates (16 countries); 7. One cancer registry covering a part of a country as a repre-
sentative of the country profile (11 countries); 8. Age/sex specific rates for ‘all cancers’ partitioned using data on the relative frequency 
of different cancers (by age and sex) (12 countries); and 9. The rates are those of neighbouring countries or registries in the same area 
(33 countries) [17, 18].
Age-specific mortality rate estimate 
Depending on the degree of detail and accuracy of the national mortality data, six methods have been utilised in the following order of 
priority:
1. Rates projected to 2012 (69 countries); 2. Most recent rates applied to 2012 population (26 countries); 3. Estimations as the weighted 
average of regional rates (one country); 4. Estimations from national incidence by modeling, using country-specific survival (two countries); 
5. Estimations from national incidence using modeled survival (83 countries); and 6. The rates of neighbouring countries or registries in the 
same area (three countries) [17–19].
Human development index
The HDI is a composite measure of indicators along with three dimensions: life expectancy, educational attainment, and command over 
the resources needed for a decent living. All groups and regions had notable improvement in all HDI components, with faster progress in 
low and medium HDI countries. On this basis, the world is becoming less unequal. Nevertheless, national averages hide large variations 
in human experience. Wide disparities remain within countries, both in the North and the South, and income inequality within and between 
many countries has been rising [16].
Statistical analysis
In this study, we used the correlation bivariate method for assessment of the correlation between age ASR and HDI, and its details 
including life expectancy at birth, mean years of schooling, and gross national income (GNI) per capita. Statistical significance was 
assumed if P < 0.05. All reported P-values are two-sided. Statistical analyses were performed using SPSS (Version 15.0, SPSS Inc).
Results
In general, Asian countries recorded 110,526 cases of ovarian cancer in 2012. Among these countries, the five countries with the highest 
number of cases were China (34,575 cases), India (26,834 cases), Indonesia (10,238 cases), Japan (8921 cases), and Pakistan (3703 
cases). The five countries included 84,271 cases (24/76%) of patients in Asia.
In Asian countries, five countries had the highest standardised incidence of ovarian cancer, as follows: Singapore with 9.9 per 100,000, 
Kazakhstan with 7.9 per 100,000, Beruni with 8.8 per 100,000, Armenia with 5.8 per 100,000, and Japan with 4.8 per 100,000, respectively. 
The five countries with the lowest standardised rates of ovarian cancer were Tajikistan with 2 per 100,000, Uzbekistan with 2.1 per 100,000, 
Azerbaijan with 2.1 per 100,000, Turkmenistan with 2.6 per 100,000, and Vietnam with 2.6 per 100,000 (Table and Figure 1).
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Table 1. Number, crude and standardised incidence rates, and mortality from ovarian cancer in Asian countries in 2012 (sorted by 
age-standardised rate from the highest to lowest).
Ovary - Estimated incidence, all ages Ovary - Estimated mortality, all ages
POPULATION Numbers Crude Rate ASR (W) POPULATION Numbers Crude Rate ASR (W)
Singapore 371 14.2 9.9 Indonesia 7075 5.8 6.1
Kazakhstan 939 11.0 9.7 Brunei 9 4.4 6.0
Brunei 16 7.8 8.8 Kazakhstan 608 7.1 6.0
Armenia 193 11.6 8.5 Armenia 130 7.8 5.1
Japan 8921 13.7 8.4 Israel 296 7.6 5.1
Indonesia 10,238 8.3 8.4 United Arab Emirates 42 1.7 5.0
Malaysia 1098 7.6 7.8 Kyrgyzstan 113 4.1 5.0
Lebanon 183 8.3 7.5 Malaysia 645 4.5 4.9
Israel 380 9.8 7.3 Maldives 5 3.1 4.8
Maldives 9 5.6 7.1 State of Palestine 54 2.6 4.7
Korea, Democratic 
Republic of
1089 8.7 6.8 Nepal 528 3.4 4.7
Korea, Republic of 2349 9.6 6.8 Lebanon 116 5.3 4.7
United Arab Emirates 72 2.9 6.4 Pakistan 2726 3.1 4.5
Kyrgyzstan 158 5.7 6.3 Myanmar 1040 4.2 4.3
Turkey 2400 6.4 6.3 Timor-Leste 12 2.1 4.3
Thailand 2689 7.6 5.9 Turkey 1588 4.3 4.2
Philippines 2425 5.0 5.9 Lao PDR 94 2.9 4.2
Sri Lanka 736 6.8 5.8 Singapore 166 6.4 4.0
Nepal 702 4.5 5.8 Philippines 1442 3.0 3.9
State of Palestine 78 3.7 5.7 Jordan 71 2.3 3.8
Pakistan 3703 4.2 5.6 Bhutan 10 2.8 3.8
Myanmar 1396 5.6 5.5 Bangladesh 2166 2.9 3.7
Jordan 111 3.5 5.4 Sri Lanka 487 4.5 3.6
Lao PDR 129 4.0 5.2 India 19549 3.2 3.6
Bhutan 15 4.3 5.2 Syrian Arab Republic 262 2.5 3.6
Timor-Leste 16 2.7 5.1 Cambodia 219 3.0 3.6
India 26,834 4.4 4.9 Afghanistan 266 1.6 3.5
Syrian Arab Republic 385 3.7 4.8 Iraq 347 2.1 3.5
Iran, Islamic  
Republic of
1637 4.4 4.8 Japan 4986 7.7 3.4
Kuwait 31 2.7 4.7 Qatar 8 1.7 3.4
Qatar 14 3.0 4.6 Iran, Islamic Republic of 1076 2.9 3.4
Cambodia 300 4.1 4.5 Yemen 202 1.6 3.4 
Bahrain 15 2.9 4.4 Kuwait 18 1.5 3.3 
Bangladesh 2912 3.9 4.4 Korea, Democratic 
Republic of
551 4.4 3.2 
Iraq 488 2.9 4.3 Mongolia 36 2.5 3.2 
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Table 1. (Continued.)
Ovary - Estimated incidence, all ages Ovary - Estimated mortality, all ages
POPULATION Numbers Crude Rate ASR (W) POPULATION Numbers Crude Rate ASR (W)
China 34575 5.3 4.1 Thailand 1431 4.0 3.1 
Yemen 275 2.2 3.8 Oman 17 1.4 2.7 
Afghanistan 346 2.1 3.8 Korea, Republic of 1054 4.3 2.5 
Georgia 128 5.6 3.7 Saudi Arabia 190 1.5 2.5 
Mongolia 46 3.2 3.7 Bahrain 9 1.8 2.4 
Saudi Arabia 307 2.4 3.4 Georgia 82 3.6 2.1 
Oman 25 2.1 3.3 Turkmenistan 47 1.8 2.1 
Viet Nam 1254 2.8 2.6 Viet Nam 887 2.0 1.9 
Turkmenistan 65 2.5 2.6 Tajikistan 43 1.2 1.8 
Azerbaijan 141 3.0 2.5 Azerbaijan 93 2.0 1.7 
Uzbekistan 275 1.9 2.1 China 14676 2.2 1.7 
Tajikistan 57 1.6 2.0 Uzbekistan 196 1.4 1.7 
Figure 1. standardised incidence and mortality rates of ovarian cancer in Asia in 2012.
The number of 65,668 deaths because of ovarian cancer occurred in Asian countries in 2012. The greatest number of deaths were in India 
(19,549), China (14,676), Indonesia (7075), Japan (4986), and Pakistan (2726). The total number of deaths in the five countries was 49,012 
(63/74%).
In Asian countries, the five countries with the highest standardised death rate of ovarian cancer were as follows: Indonesia 1.6 per 100,000, 
Brunei with 6 per 100,000, Kazakhstan with 6 per 100,000, Armenia with 5.1 per 100,000, and Israel with 5.1 per 100,000. The five coun-
tries with the lowest standardised mortality rate of ovarian cancer included Uzbekistan with 7.1 per 100,000, China with 1.7 per 100,000, 
Azerbaijan with 1.7 per 100,000, Tajikistanwith 1.8 per 100,000, and Vietnam with 1.9 per 100,000 (Table and Figure 1).
Table 2 shows values of the HDI and its components for each of the Asian countries. The Asian countries in terms of HDI are classified as 
follows: the three countries in the very high category, four countries in the high category, thirty-five countries in the middle category, three 
countries in the low category, and one country in the unknown category.
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Table 2. Human Development Index in Asian countries in 2012.
HDI POPULATION Human 
Development 
Index (HDI)
Life expectancy at 
birth
Mean Year of 
schooling
Gross national 
income (GNI) per 
capita
Very high Japan 0.912 83.6 11.6 32545
Korea, Republic of 0.909 80.7 11.6 28,231
Israel 0.9 81.9 11.9 26,224
High Singapore 0.895 81.2 10.1 52,613
Brunei 0.855 78.1 8.6 45,690
Qatar 0.834 78.5 7.3 87478
United Arab  
Emirates
0.818 76.7 8.9 42,716
Medium Bahrain 0.796 75.2 9.4 19,154
Kuwait 0.79 74.7 6.1 52,793
Saudi Arabia 0.782 74.1 7.8 22,616
Malaysia 0.769 74.5 9.5 13,676
Kazakhstan 0.754 67.4 10.4 10,451
Georgia 0.745 73.9 12.1 5005
Lebanon 0.745 72.8 7.9 12,364
Iran, Islamic  
Republic of
0.742 73.2 7.8 10,695
Azerbaijan 0.734 70.9 11.2 8153
Oman 0.731 73.2 5.5 24,092
Armenia 0.729 74.4 10.8 5540
Turkey 0.722 74.2 6.5 13,710
Sri Lanka 0.715 75.1 9.3 5170
Jordan 0.7 73.5 8.6 5272
China 0.699 73.7 7.5 7945
Turkmenistan 0.698 65.2 9.9 7782
Thailand 0.69 74.3 6.6 7722
Maldives 0.688 77.1 5.8 7478
Mongolia 0.675 68.8 8.3 4245
State of Palestine 0.67 73 8 3359
Philippines 0.654 69 8.9 3752
Uzbekistan 0.654 68.6 10 3201
Syrian Arab  
Republic
0.648 76 5.7 4674
Indonesia 0.629 69.8 5.8 4154
Kyrgyzstan 0.622 68 9.3 2009
Tajikistan 0.622 67.8 9.8 2119
Viet Nam 0.617 75.4 5.5 2970
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Table 2. (Continued.)
HDI POPULATION Human 
Development 
Index (HDI)
Life expectancy  
at birth
Mean Year of 
schooling
Gross national 
income (GNI) per 
capita
Iraq 0.59 69.6 5.6 3557
Timor-Leste 0.576 62.9 4.4 5446
India 0.554 65.8 4.4 3285
Cambodia 0.543 63.6 5.8 2095
Lao PDR 0.543 67.8 4.6 2435
Bhutan 0.538 67.6 2.3 5246
Bangladesh 0.515 69.2 4.8 1785
Pakistan 0.515 65.7 4.9 2566
Low Myanmar 0.498 65.7 3.9 1 817
Nepal 0.463 69.1 3.2 1137
Yemen 0.458 65.9 5.3 928
Afghanistan 0.374 49.1 3.1 1000
Unknown Korea, Democratic 
Republic of
– – – –
Figure 2. Correlation between HDI and standardised incidence rates of ovarian cancer in Asia in 2012.
Standardised incidence rate and HDI
The standardised incidence rate for ovarian cancer had a positive correlation with the HDI, which was statistically significant (p = 0.006).
There was a positive correlation between the components of the HDI and standardised incidence rate, so that a positive correlation was 
seen between the standardised incidence rate and life expectancy at birth (p = .006), the standardised incidence rate and the average 
years of schooling (0.143), and the standardised incidence rate and the level of income per person of population (p = 0.063) (Figure 2).
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The standardised mortality rate and HDI
The standardised mortality rate for ovarian cancer had a negative correlation with the Human Development Index and this association was 
not statistically significant (p = 0.975). Between the components of the HDI and standardised mortality rate, statistically significant correla-
tion was not observed. So that a positive correlation between the standardised mortality and life expectancy at birth (p = 0.861), a negative 
correlation between the standardised mortality and mean years of schooling (0.373), and a positive correlation between the standardised 
mortality and the level of income for each person (p = 0.664) (Figure 3).
Discussion
According to the findings of this study among Asian countries, Singapore, Kazakhstan, and Brunei had the highest standardised incidence 
rate of ovarian cancer. Studies also showed that Singapore has a high HDI, and the other two countries fell in the middle of the scale. Among 
these countries, the five countries with the highest rate of ovarian cancer included 84% of cancer cases related to Asian countries. Among 
these countries, Japan had a very high HDI and four other countries were in the middle of the scale. For standardised incidence rate, Singapore 
had the highest standardised incidence, and Tajikistan had the lowest. Our data in terms of the relationship between HDI and the standardised 
incidence rate showed that countries with HDI had a high-standardised incidence rate, and this finding was statistically significant.
The standardised mortality rate of ovarian cancer showed that five countries, including India, China, Indonesia, Japan, and Pakistan, had 
the highest rate of mortality. Overall, the countries included 63.74% of all deaths from ovarian cancer. There was no significant correlation 
between the HDI and standardised mortality rate.
In the absence of screening for ovarian cancer, diagnosis of this disease in the advanced stages leads to this cancer being considered as 
a fatal disease [19]. Most of the patients are diagnosed in stage 3 (71%) or stage 4 (31%). In other words, identifying this disease is hard, 
and the survival rate of the disease is low [20]. In addition, it has higher mortality among gynaecological cancers [20].
Figure 3. Correlation between HDI and standardised mortality rates for ovarian cancer in Asia in 2012.
We also found that in the past, most of the world’s population was made up of children and teenagers, but with ageing (increased longev-
ity) and a decrease in the birth rate, the declining population in the future will be remarkable. Because of increasing life expectancy and 
decreasing birth rate, the world has become ageing, and problems such as non-communicable diseases, especially cancer in the coming 
years are increasing. Most of the Asian countries are young, and the pattern of western lifestyle in these countries is progressive. Therefore, 
this problem will have a particular impact on developing countries.
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According to the World Health Organisation in 2012, the increasing rate of older populations may lead to an increase in new cancer cases 
up to 19.3 million in 2025. Most new cases (56.8%) and mortality (64.9%) will occur in developing countries [17]. It is estimated that can-
cer causes 12.6% of total deaths. It is the second cause of death after heart disease. It is expected that cancer deaths will exceed those 
because of heart disease [21]. 
Although an increased incidence was seen in most countries, the difference between developed and developing countries was significant. 
Although developed countries have the highest incidence rate of cancer, the mortality rate is higher in developing countries. A lack of 
resources in developing countries leads to late diagnosis of the disease which causes high mortality from cancer in these countries. For 
example, the incidence of breast cancer in Western Europe was 90 new cases per 100,000 people, while the annual incidence in eastern 
Africa was 30 per 100,000, and mortality from the disease in these two regions nearly equals 15 per 100,000(21).
The incidence of cancer in the different geographic regions can partly be attributed to differences in risk factors related to lifestyle [22]. 
Several factors affect the occurrence of cancer, including tobacco, alcohol, work-related factors, pollution, water pollution, food and nutri-
tion, obesity, physical activity, infectious agents, and UV radiation [23]. Related risk factors in developed countries include smoking, the 
pattern of nutritional, and reproductive behaviours, and in developing countries infectious agents, but disease patterns are changing [22]. 
One of the important factors in reducing the incidence and mortality of cancer can be HDI. The scale evaluates the long-term progress in 
three areas of human development. It is a composite index of three basic dimensions of human development, including life expectancy at 
birth, educational attainment (based on a combination of adult literacy rate and primary to tertiary education enrolment rates), and income 
(based on GDP per head, adjusted for purchasing-power parity in US$) (United Nations Development Programme: Human Development 
Index [HDI] [24].
Because of the lack of screening for ovarian cancer, its identification occurs at advanced stages, improving standard criteria in HDI, and 
awareness about lifestyle modification can partly prevent the incidence and mortality of this deadly disease.
Limitations
This was an ecological study. Result of this type of study should be interpreted at the population level, and ecological fallacy will occur if 
results are inferred and concluded at the individual level. Some other factors such as the number of reproductive and contraceptive factors 
that suppress ovulation, including gravidity, breast feeding, and oral contraception, reduce the risk of ovarian cancer, and gynaecologic sur-
geries including hysterectomy and tubal ligation were protective. Some of the environmental factors and medical conditions that increased 
risk of disease included talc use, endometriosis, ovarian cysts, and hyperthyroidism. However, in this study we do not have access to 
enough information on these factors to consider their role in the incidence and mortality of ovarian cancer in Asian countries. Therefore, it 
is suggested that in addition to ecological studies, in each of these countries, studies in the form of case-control or cohort studies should 
be done to determine the role of factors related to the incidence and mortality from this disease on an individual level.
Conclusions
Based on the findings of this study, ovarian cancer as a fatal disease in countries with low HDI had an increasing trend. The increasing 
number of elderly people in these countries, the changes in the way of life in these countries, as well as lack of facilities for screening in 
turn leading to delayed diagnosis, will all contribute towards these countries having to face rising mortality from this disease. Therefore, 
it seems that health policy makers should make serious decisions in this area to deal with the increase in the incidence and mortality of 
ovarian cancer. Asian countries are mostly developing countries, and the Western lifestyle in these countries causes a rapid increase in 
the burden of non-communicable diseases. Preventive programmes should be the top priority in these countries. In general, it can be 
concluded that by improving the socioeconomic situation, we find the incidence and mortality from infectious diseases and cancers related 
to infection are reduced, but cancers which are more associated with lifestyle factors are in rise. 
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